# Integrating MICRORNA941 and T cell subset research into public health strategies for managing inflammaging in elderly and immune-compromised patients

## TL;DR

This paper explores how miR-941 and T cell subsets could help manage inflammaging in elderly and immune-compromised patients, potentially improving public health strategies.

## Contribution

The paper proposes targeted research on miR-941's effects on T-cell subsets to address age-related immune decline and chronic diseases.

## Key findings

- miR-941 regulates T-cell subsets crucial for immune surveillance in aging and immune-compromised individuals.
- Targeting miR-941 could lead to better treatments for infectious and chronic diseases in the elderly.
- Research on miR-941 may improve public health accessibility and affordability for managing inflammaging.

## Abstract

As of 2022, the Centers for Disease Control and Prevention (CDC) reported that the average life expectancy for both sexes in the
United States is 77.5 years. While new advances in health have increased life expectancy, aging comes with complications that impact the
development of diseases like cancer, senile dementia (non-Alzheimer), diabetes and Parkinson's. Through aging, the body's immune system
declines, a process recognized as immunosenescence and which contributes to inflammaging, a state of chronic, though non-productive,
inflammation that progresses with advancing age in the absence of overt infection and that contributes to the onset and progression of a
spectrum of age-related pathologies. MicroRNAs are small forms of RNA that control gene expression by binding to messenger RNA (mRNA) in
the cell cytoplasm. In particular, microRNA-941 (miR-941) has been found to play a critical role in the regulation of differentiation of
cell populations, certain T cell subsets responsible for maintaining efficient immune surveillance in normal subjects, immune compromised
individuals as well as the elderly. We propose that concerted research designed to define and characterize interventions targeting the
regulatory effects of miRNA-941 specifically on T-cell subsets will benefit treatment of infectious (e.g., CoViD-19,
H5N1 infection) and chronic illnesses (e.g., diabetes II, diabetes III, Long Covid [i.e., Post-Acute
Covid-19 Syndrome, PACS], autoimmune disease), which are most common among the aging and the immune compromised population. It is
possible and even probable that active research in this specific area will proffer new horizons for finding cures, aid in disease
management and improved accessibility and affordability of public health services.